Suggested searches

Adam Denley

Principal | BBiotech (Hons), PhD, MIP Law
Direct number




About Adam

Developing patent strategies to take transformative healthcare innovations to clinic - and ultimately to market.

Adam is a Trans-Tasman registered patent attorney specialising in the drafting and prosecution of global patent families related to the biotechnology and pharmaceutical fields. 

With a lifelong passion for the potential of medical innovation to change lives, Adam uses his extensive technical and commercial expertise to take groundbreaking medical patents from conception through to reality.

Highly regarded for his collaborative approach, he works closely with companies and researchers to capture their commercially valuable IP. He specialises in building complex patent portfolios which are both attractive to investors and able to withstand the rigours of prosecution and enforcement.

Adam provides tailored commercial advice on the basis of a thorough understanding of his clients’ inventions and business goals. He regularly works with investors to conduct due diligence work on patent families, identifying and advising on any risks that arise.

Adam also provides strategic advice to his clients regarding the enforcement and defence of patent rights, and regularly leads oppositions before the Australian Patent Office.

Before joining FPA, Adam spent nearly three years as a postdoctoral fellow in the Department of Molecular and Experimental Medicine at The Scripps Research Institute in La Jolla, USA. His research was focused on protein and lipid kinases in cell transformation, and identifying small molecules as potential lead compounds for cancer therapeutics.

Adam regularly writes articles on the interface between biotechnology and patent law, with a particular focus on therapeutic antibodies, diagnostics, isolated nucleic acids and biomarkers.

Adam has authored 14 peer reviewed articles and reviews in journals such as Molecular and Cellular Biology, The EMBO Journal and the Proceedings of the National Academy of Science of the United States of America. Articles can be viewed at the US National Library of Medicine, National Institutes of Health (PubMed).


  • Ranked as a ‘Recommended Individual’ by IAM Patent 1000, 2018-2024


  • Bachelor of Biotechnology (First Class Honours), Flinders University
  • Doctor of Philosophy in Biochemistry, The University of Adelaide
  • Master of Intellectual Property Law, The University of Melbourne
  • Registered Trans-Tasman Patent Attorney


  • Fellow, Institute of Patent & Trade Mark Attorneys of Australia (IPTA)
  • Royal Australian Chemical Institute
  • AusBiotech

…this is a significant value inflection point for our company and a great achievement. There were many individual decisions and judgement calls we made together, based on many discussions with you and your team, and they have all led to this magnificent outcome… Thank you for the on-going focus, energy and commitment you have brought so far. I’m looking forward to continuing our work together to strengthen the IP protection around our exciting technology.

Latest articles authored by Adam Denley — 19 November 2019

Enablement and Support in Australia (part 2 of 3)

Latest articles authored by Adam Denley — 2 July 2019

Sequenom v Ariosa: Methods of diagnosis held patentable in Australia

Latest articles authored by Adam Denley — 18 January 2019

Generous patent grace period changes in Japan

Latest articles authored by Adam Denley — 24 August 2017

Patentability of diagnostic methods and biomarkers in Australia and New Zealand

Latest articles authored by Adam Denley — 23 February 2017

Swiss-style patent claims can be very valuable in Australia


Awards & Recognition

Scroll to Top

Suggested searches

Skip to content